Key result
The joint effect of the NOS3 rs869109213 and EDNRB rs10507875 polymorphisms (dominant × dominant model) was associated with a 4.15-fold increased risk of diabetic retinopathy in patients with type 2 diabetes.
Why the study?
Do EDNRB rs10507875 and NOS3 rs869109213 polymorphisms increase the risk of diabetic retinopathy in patients with type 2 diabetes mellitus?
Case-Control (n=526)
Yes
Do EDNRB rs10507875 and NOS3 rs869109213 polymorphisms increase the risk of diabetic retinopathy in patients with type 2 diabetes mellitus?
The NOS3 rs869109213 polymorphism, alone or in combination with the EDNRB rs10507875 polymorphism, is associated with an increased risk of diabetic retinopathy in Caucasian patients with type 2 diabetes.
Answers are grounded in this paper and cite their sources.
May inform future risk models in type 2 diabetes; hypothesis-generating and should not yet change practice.
Increasing evidence suggests that endothelin and nitric oxide synthase genes and their products exert biological effects on the vasculature via the nitric oxide or endothelin pathway. The aim of the study was to evaluate the association of rs10507875 and rs869109213 (alone or in interaction) with diabetic retinopathy (DR) in subjects with type 2 diabetes mellitus (T2DM). We genotyped the single nucleotide polymorphism rs10507875 of the endothelin receptor B gene (EDNRB) and variable number tandem repeats rs869109213 of the nitric oxide synthase 3 gene (NOS3) in 270 Slovenian patients with DR and T2DM and 256 controls with T2DM without clinical signs of DR. The genotyping was performed using either real-time polymerase chain reaction (PCR) or standard PCR. We found a significant association between the genotypes of NOS3 rs869109213 polymorphism and the risk of DR in the co-dominant model (4a4b genotype; 1.99-fold increased risk [1.09-3.65]; 95% confidence interval [CI]; p = 0.02), co-dominant model (4a4a genotype; 4.16-fold increased risk [1.03-16.74]; 95% CI; p = 0.04), and dominant model (4a4a and 4a4b genotypes; 2.22-fold increased risk [1.26-3.92]; 95% CI; p = 0.01) compared to the 4b4b genotype. Moreover, the joint effect of the two polymorphisms on DR risk was greater than the individual effect of each polymorphism in the analyzed genetic models. Additionally, adjusted odds ratio showed an increased risk in dominant × dominant (4.15-fold [1.40-12.26]; 95% CI; p = 0.01) and recessive × dominant (2.24-fold [1.25-4.01]; 95% CI; p = 0.02) genotype combinations of the two polymorphisms. In conclusion, our results indicate that NOS3 rs869109213 polymorphism alone or in a combination with EDNRB rs10507875 polymorphism may be associated with DR in Slovenian patients with T2DM.
No takes yet. Share an insight, caveat, or question.
Bregar et al. (2017) conducted a case-control in Type 2 diabetes mellitus and diabetic retinopathy (n=526). NOS3 rs869109213 and EDNRB rs10507875 polymorphisms vs. Wild-type genotypes was evaluated on Risk of diabetic retinopathy (joint effect dominant × dominant model) (OR 4.15, 95% CI 1.40-12.26, p=0.01). The joint effect of the NOS3 rs869109213 and EDNRB rs10507875 polymorphisms (dominant × dominant model) was associated with a 4.15-fold increased risk of diabetic retinopathy in patients with type 2 diabetes.
Synapse has enriched 10 related papers. Consider them for comparative context: